数字Uromonitor在非肌层浸润性膀胱癌监测中优于qPCR和细胞学
本研究基于EVALUATION-CUETO前瞻性多中心队列的回顾性分析,重新检测271份尿液DNA样本,比较数字Uromonitor(dUM)与qPCR版Uromonitor及细胞学在NMIBC随访中的性能。dUM检测复发敏感性72%,显著高于qPCR的36%和细胞学的34%,特异性88%,NPV 93%,AUC 0.80优于qPCR的0.66;与膀胱镜联合时PPV从79%提升至94%。
要点
- dUM检测NMIBC复发敏感性72%,优于qPCR的36%和细胞学的34%。
- dUM特异性88%,NPV 93%,AUC 0.80优于qPCR的0.66。
- 膀胱镜阳性/可疑联合dUM阳性时PPV升至94%(膀胱镜单独79%)。
核心结论
- 数字Uromonitor在真实世界中检测NMIBC复发的敏感性显著优于qPCR predecessor和细胞学,且不牺牲特异性。
- 其高NPV支持减少不必要膀胱镜的潜力,与膀胱镜联合大幅提高PPV,可能作为辅助工具提高诊断信心并减少不必要的经尿道膀胱肿瘤电切,尚待成本效益验证。
研究设计与样本
- 基于EVALUATION-CUETO研究(NCT05864599)前瞻性收集的多中心队列,进行回顾性(post hoc)分子分析。
- 重新分析271份储存尿液DNA样本,使用dUM(QX200 Droplet Digital PCR系统)检测TERT和FGFR3热点突变,并与qPCR版Uromonitor及细胞学比较。
- 以膀胱镜/组织学为参照计算复发检测的敏感性、特异性、PPV、NPV和AUC。
主要发现
- 271份样本分析显示,dUM敏感性72%,高于qPCR的36%和细胞学的34%。
- dUM保持高特异性88%和高NPV 93%。
- dUM的AUC为0.80,qPCR为0.66。
- 性能在不同肿瘤分级和风险组中一致。
- 膀胱镜阳性/可疑联合dUM阳性时,PPV显著增至94%(膀胱镜单独为79%)。
关键数值与推荐
- dUM敏感性72% vs qPCR 36% vs细胞学34%。
- dUM特异性88%,NPV 93%。
- dUM AUC 0.80 vs qPCR 0.66。
- 膀胱镜联合dUM阳性PPV 94%(膀胱镜单独79%)。
临床怎么用
- dUM可作为NMIBC随访中高敏感性无创检测,高NPV支持其减少不必要膀胱镜的潜力。
- 与膀胱镜联合可提高诊断信心,可能减少不必要的经尿道膀胱肿瘤电切,但需考虑成本效益。
局限性
- 回顾性(post hoc)分析储存样本,非前瞻性验证。
- 原文未报告成本效益数据,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the performance of a new digital Uromonitor® (dUM; U-Monitor, Porto, Portugal) against the previous quantitative polymerase chain reaction (qPCR) version and cytology in the follow-up of non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: This retrospective (post hoc) molecular analysis of a prospectively collected multicentre cohort re-analysed stored urine DNA samples from the 'External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Management by the Club Urológico Español de Tratamiento Oncológgico Group' (EVALUATION-CUETO) study (ClinicalTrials.gov identifier: NCT05864599). Samples, previously tested with Uromonitor-version 2, were analysed using dUM (QX200™ Droplet Digital PCR System) for TERT and FGFR3 hotspot mutations. Performance metrics (sensitivity, specificity, positive predictive value [PPV], negative predictive value [NPV], area under the curve [AUC]) for detecting recurrence were calculated against cystoscopy/histology and compared to qPCR and cytology. The study received approval from the Ethical Committee at the University Hospital of Vall d'Hebron (Barcelona). RESULTS: Analysis of 271 samples revealed dUM had superior sensitivity to qPCR (72% vs 36%) and cytology (72% vs 34%), while preserving high specificity (88%) and NPV (93%). The AUC for dUM was 0.80 vs 0.66 for qPCR. Performance was consistent across tumour grades and risk groups. Crucially, combining a positive/suspicious cystoscopy with a positive dUM result significantly increased the PPV to 94% (from 79% for cystoscopy alone). CONCLUSION: The dUM significantly outperformed its qPCR predecessor and cytology in sensitivity for detecting NMIBC recurrence in a real-world setting, without compromising specificity. Its high NPV supports its potential for reducing unnecessary cystoscopies. Furthermore, its combination with cystoscopy drastically increased the PPV, suggesting a role as an adjunctive tool to improve diagnostic confidence and potentially reduce unnecessary transurethral resections of bladder tumour, pending favourable cost-effectiveness.
引用
- Rubio-Briones J, Guerrero Ramos F, Mercadé Sánchez A, et al. Digital Uromonitor® outperforms quantitative polymerase chain reaction Uromonitor and cytology for non-muscle-invasive bladder cancer surveillance: results from the 'External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Management by the Club Urológico Español de Tratamiento Oncológico Group' (EVALUATION-CUETO) study. BJU Int. 2026. PMID: 41941336. doi:10.1111/bju.70230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。